Quality of life in patients with non-muscle invasive bladder tumor undergoing adjuvant intravesical treatment.
Actas Urol Esp (Engl Ed)
; 47(6): 360-368, 2023.
Article
en En, Es
| MEDLINE
| ID: mdl-36746347
ABSTRACT
INTRODUCTION:
The objective of the study was to establish a possible relationship between mitomycin-C (MMC) and bacillus Calmette-Guérin (BCG) treatments and quality of life impairment. MATERIAL ANDMETHODS:
Quasi-experimental, prospective, and longitudinal study including patients undergoing adjuvant treatment in NMIBC. The Short form-12 (SF-12) and Urogenital Distress Inventory-6 (UDI-6) questionnaires were used to measure quality of life. Questionnaire scores were compared between cases with MMC and BCG before induction (M1), at 4 weeks (M2) and at 2 months (M3).RESULTS:
Of the 90 patients enrolled, 54 were in the BCG group and 36 in the MMC group. It was found that BCG patients had worse perceived physical quality of life compared to MMC patients in M2 (OR2.59, p=0.046). In addition, significant changes were found in the urinary quality of life of patients on MMC treatment between the different time points (UDI-6 score 33.33 in M1, 27.78 in M2 and 16.67 in M3, p=0.001).CONCLUSIONS:
There are no differences in urinary quality of life between patients treated with MMC and BCG. Patients with MMC show a significant recovery of urinary quality of life from the completion of the induction course, which becomes even more significant after 2 months. In addition, BCG-treated patients have worse physical quality of life after 4 weeks of treatment than those treated with MMC.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neoplasias de la Vejiga Urinaria
/
Antibióticos Antineoplásicos
Tipo de estudio:
Observational_studies
Aspecto:
Patient_preference
Límite:
Humans
Idioma:
En
/
Es
Revista:
Actas Urol Esp (Engl Ed)
Año:
2023
Tipo del documento:
Article